SIGA Quote, Financials, Valuation and Earnings

Palatin Technologies has a net margin of 56.17% compared to SIGA Technologies's net margin of -2357.27%. SIGA Technologies's return on equity of 32.37% beat Palatin Technologies's return on equity of --.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 772.06%. Given that Palatin Technologies has higher upside potential than SIGA Technologies, analysts believe Palatin Technologies is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 0.976, which suggesting that the stock is 2.414% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 72.05% of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $81.5M, which are larger than Palatin Technologies quarterly revenues of $350K. SIGA Technologies's net income of $45.8M is higher than Palatin Technologies's net income of -$2.4M. Notably, SIGA Technologies's price-to-earnings ratio is 7.00x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 2.97x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 56.17% compared to SIGA Technologies's net margin of --. SIGA Technologies's return on equity of 32.37% beat Theriva Biologics's return on equity of --.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 412.82%. Given that Theriva Biologics has higher upside potential than SIGA Technologies, analysts believe Theriva Biologics is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 0.976, which suggesting that the stock is 2.414% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 72.05% of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $81.5M, which are larger than Theriva Biologics quarterly revenues of --. SIGA Technologies's net income of $45.8M is higher than Theriva Biologics's net income of -$4.4M. Notably, SIGA Technologies's price-to-earnings ratio is 7.00x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 2.97x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of 56.17% compared to SIGA Technologies's net margin of -549.33%. SIGA Technologies's return on equity of 32.37% beat Voyager Therapeutics's return on equity of -21.07%.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Voyager Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 293.64%. Given that Voyager Therapeutics has higher upside potential than SIGA Technologies, analysts believe Voyager Therapeutics is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 0.976, which suggesting that the stock is 2.414% less volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.87699999999999%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 72.05% of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $81.5M, which are larger than Voyager Therapeutics quarterly revenues of $6.3M. SIGA Technologies's net income of $45.8M is higher than Voyager Therapeutics's net income of -$34.5M. Notably, SIGA Technologies's price-to-earnings ratio is 7.00x while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 2.97x versus 2.95x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of 56.17% compared to SIGA Technologies's net margin of -296.76%. SIGA Technologies's return on equity of 32.37% beat Zevra Therapeutics's return on equity of -208.85%.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Zevra Therapeutics has an analysts' consensus of $21.63 which suggests that it could grow by 160.23%. Given that Zevra Therapeutics has higher upside potential than SIGA Technologies, analysts believe Zevra Therapeutics is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 0.976, which suggesting that the stock is 2.414% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.977, suggesting its more volatile than the S&P 500 by 97.719%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 72.05% of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $81.5M, which are larger than Zevra Therapeutics quarterly revenues of $12M. SIGA Technologies's net income of $45.8M is higher than Zevra Therapeutics's net income of -$35.7M. Notably, SIGA Technologies's price-to-earnings ratio is 7.00x while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 2.97x versus 16.27x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.